Figures & data
Table 1 Demographic and baseline characteristics (safety population)
Table 2 Summary of adverse events (safety population)
Figure 2 Mean (± standard error) change in hemoglobin A1c(HbA1c) with colesevelam (3.75 g/day) versus a placebo in the double-blind phase (starting at baseline A) when added to metformin-based treatment in patients with inadequately controlled type 2 diabetes mellitus (safety population). In the open-label extension phase (starting at baseline B), all study participants received colesevelam (3.75 g/day).
![Figure 2 Mean (± standard error) change in hemoglobin A1c(HbA1c) with colesevelam (3.75 g/day) versus a placebo in the double-blind phase (starting at baseline A) when added to metformin-based treatment in patients with inadequately controlled type 2 diabetes mellitus (safety population). In the open-label extension phase (starting at baseline B), all study participants received colesevelam (3.75 g/day).](/cms/asset/7084be41-f708-48ad-907a-9b55b2d7b369/dmso_a_32018_f0002_b.jpg)
Figure 3 Mean (± standard error) change in fasting plasma glucose with colesevelam (3.75 g/day) versus the placebo in the double-blind phase (starting at baseline A) when added to metformin-based treatment in patients with inadequately controlled type 2 diabetes mellitus (safety population). In the open-label extension phase (starting at baseline B), all study participants received colesevelam (3.75 g/day).
![Figure 3 Mean (± standard error) change in fasting plasma glucose with colesevelam (3.75 g/day) versus the placebo in the double-blind phase (starting at baseline A) when added to metformin-based treatment in patients with inadequately controlled type 2 diabetes mellitus (safety population). In the open-label extension phase (starting at baseline B), all study participants received colesevelam (3.75 g/day).](/cms/asset/a81e5f50-3fc1-43d7-8ca0-b1ccf436a4d2/dmso_a_32018_f0003_b.jpg)
Figure 4 Mean (± standard error)* change in lipids and apolipoproteins with colesevelam (3.75 g/day) in the double-blind phase (starting at baseline A) when added to metformin-based treatment in patients with inadequately controlled type 2 diabetes mellitus (safety population). In the open-label extension phase (starting at baseline B), all study participants received colesevelam (3.75 g/day).
Abbreviations: Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
![Figure 4 Mean (± standard error)* change in lipids and apolipoproteins with colesevelam (3.75 g/day) in the double-blind phase (starting at baseline A) when added to metformin-based treatment in patients with inadequately controlled type 2 diabetes mellitus (safety population). In the open-label extension phase (starting at baseline B), all study participants received colesevelam (3.75 g/day).](/cms/asset/9542cca7-37f5-48fd-bbdd-5bf0db8bec37/dmso_a_32018_f0004_b.jpg)